Atlas Trials

CRISPR Therapeutics AG

12 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch CRISPR Therapeutics AG

RecordFirmDate
A Trial Evaluating Safety, Tolerability and Efficacy of CTX340 in Participants With Hypertension (NCT07758634)CRISPR Therapeutics AG2026-08-08
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease (NCT07549698)CRISPR Therapeutics AG2026-06-01
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias (NCT07491172)CRISPR Therapeutics AG2024-06-21
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies (NCT06208878)CRISPR Therapeutics AG2023-11-22
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors (NCT05795595)CRISPR Therapeutics AG2023-03-13
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies (NCT05643742)CRISPR Therapeutics AG2023-03-10
An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D (NCT05565248)CRISPR Therapeutics AG2023-01-20
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) (NCT04502446)CRISPR Therapeutics AG2020-07-31
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC) (NCT04438083)CRISPR Therapeutics AG2020-06-16
A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma (NCT04244656)CRISPR Therapeutics AG2020-01-22
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) (NCT04035434)CRISPR Therapeutics AG2019-07-22

Track CRISPR Therapeutics AG automatically

Every clearance here is in the API, with alerts when new ones post.